1 Min Read
Aug 24 (Reuters) - Pharmaxis Ltd
* Boehringer Ingelheim initiates phase IIA study of compound acquired from Pharmaxis in debilitating liver disease nash Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.